Leuven HRD检测与Myriad MyChoice CDx PLUS HRD检测在PAOLA-1/ENGOT-ov25试验468例卵巢癌患者中的PARP抑制剂预测价值比较
在PAOLA-1/ENGOT-ov25试验的468例卵巢癌患者中,比较学术性Leuven HRD检测与Myriad HRD检测对奥拉帕利疗效的预测价值。Leuven与Myriad HRD状态的一致率分别为阳性95%、阴性86%、总体91%。在Leuven HRD+患者中,奥拉帕利组5年PFS为48.6% vs 安慰剂组20.3%(HR 0.431),与Myriad检测的HR 0.409相似。
要点
- Leuven与Myriad HRD检测阳性一致率95%、阴性一致率86%、总体一致率91%。
- Leuven HRD+患者中奥拉帕利组5年PFS 48.6% vs 安慰剂组20.3%(HR 0.431)。
- Leuven HRD+患者中奥拉帕利组5年OS 67.2% vs 安慰剂组54.4%(HR 0.663)。
核心结论
- Leuven HRD检测与Myriad检测之间观察到稳健的相关性。
- 对于HRD+肿瘤,学术性Leuven HRD检测显示的PFS和OS差异与Myriad检测相似。
研究设计与样本
- 基于PAOLA-1/ENGOT-ov25随机试验的回顾性检测比较分析。
- Leuven HRD检测采用基于捕获的靶向测序,检测全基因组单核苷酸多态性及包括BRCA1、BRCA2和TP53在内的8个HR基因的编码外显子。
- 468例患者在Myriad检测后留有剩余DNA用于Leuven HRD检测。
主要发现
- Leuven与Myriad HRD状态的阳性、阴性、总体一致率分别为95%、86%、91%。
- Leuven与Myriad检测的HRD+肿瘤比例分别为55%和52%。
- Leuven HRD+患者中,奥拉帕利组5年PFS为48.6% vs 安慰剂组20.3%(HR 0.431;95%CI 0.312-0.595)。
- Myriad HRD+患者中,奥拉帕利组5年PFS的HR为0.409(95%CI 0.292-0.572)。
- Leuven HRD+/BRCAwt患者中,奥拉帕利组5年PFS为41.3% vs 安慰剂组12.6%(HR 0.497;95%CI 0.316-0.783);Myriad检测对应为43.6% vs 13.3%(HR 0.435;95%CI 0.261-0.727)。
关键数值与推荐
- Leuven HRD+患者中,奥拉帕利组5年OS为67.2% vs 安慰剂组54.4%(HR 0.663;95%CI 0.442-0.995)。
- Myriad HRD+患者中,奥拉帕利组5年OS为68.0% vs 安慰剂组51.8%(HR 0.596;95%CI 0.393-0.904)。
- Leuven与Myriad检测的HRD状态未确定比例分别为10.7%和9.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and overall survival (OS) in homologous recombination deficient (HRD) positive patients treated with olaparib, but not when HRD negative (HRD tested with MyChoice CDx PLUS [Myriad test]). PATIENTS AND METHODS: The academic Leuven HRD test consists of capture-based targeted sequencing of genome-wide single-nucleotide polymorphisms and coding exons of eight HR genes including BRCA1, BRCA2, and TP53. We compared the predictive value of the Leuven HRD versus Myriad HRD test for PFS and OS in the randomised PAOLA-1 trial. RESULTS: 468 patients had left-over DNA after Myriad testing for Leuven HRD testing. Positive/negative/overall percent agreement for the Leuven versus Myriad HRD status was 95%/86%/91%, respectively. Tumours were HRD+ in 55% and 52%, respectively. In Leuven HRD+ patients, 5years PFS (5yPFS) was 48.6% versus 20.3% (HR 0.431; 95% confidence intervals (CI) 0.312-0.595) for olaparib versus placebo, respectively (Myriad test 0.409; 95% CI 0.292-0.572). In Leuven HRD+/BRCAwt patients 5yPFS was 41.3% versus 12.6% (HR 0.497; 95% CI 0.316-0.783), and 43.6% versus 13.3% (HR 0.435; 95% CI 0.261-0.727) for the Myriad test. 5yOS was prolonged in the HRD+ subgroup with both tests 67.2% versus 54.4% (HR 0.663; 95% CI 0.442-0.995) for the Leuven test, and 68.0% versus 51.8% (HR 0.596 95% CI 0.393-0.904) for the Myriad test. HRD status was undetermined in 10.7% and 9.4% of the samples, respectively. CONCLUSIONS: A robust correlation between the Leuven HRD and Myriad test was observed. For HRD+ tumours, the academic Leuven HRD showed a similar difference in PFS and OS as the Myriad test.
引用
- Loverix L, Vergote I, Busschaert P, et al. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial. Eur J Cancer. 2023. PMID: 37245441. doi:10.1016/j.ejca.2023.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。